FDA 483 - Boehringer Ingelheim Fremont - May 16, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspected Boehringer Ingelheim Fremont, a drug substance manufacturer, from May 8-16, 2024. The inspection revealed significant deficiencies across quality unit procedures, equipment control and qualification, facility maintenance, contamination prevention, manufacturing process validation, laboratory procedures, and adherence to BLA parameters. These issues indicate a broad lack of control over critical aspects of drug substance manufacturing, posing a moderate to severe risk to product quality and patient safety.
ID · ad0a448d-1cc1-4972-abde-e9d4a9f6b3c0